As of June 20, 2025, Kezar Life Sciences Inc (KZR) reports a EV/EBITDA of -0.06.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Kezar Life Sciences Inc's EV/EBITDA to Peers
To better understand Kezar Life Sciences Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Kezar Life Sciences Inc (KZR) | -0.06 |
| Abbvie Inc (ABBV) | 17.90 |
| Amgen Inc (AMGN) | 15.19 |
| Regeneron Pharmaceuticals Inc (REGN) | 12.66 |
| Gilead Sciences Inc (GILD) | 9.30 |
| Vistagen Therapeutics Inc (VTGN) | 0.29 |
Compared to its competitors, Kezar Life Sciences Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.